A2A Pharmaceuticals, Inc., 10% Owner at Biomea Fusion, Inc. (BMEA), sold 250,000 shares at $33.99 ($8.6M) on 2023-05-08, disclosed to the SEC on 2023-05-10.
Open-market sale of $8.6M BMEA by 10% Owner. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $33.99 | 100,000 | $3.4M | 39.6% |
| 2 | $34.50 | 150,000 | $5.2M | 60.4% |
| Total | $34.30 avg | 250,000 | $8.6M | 100% |
| Filing → |
| BMEA | SELL | 2023-04-26 | $5.8M | — | Filing → |
| BMEA | SELL | 2023-04-06 | $6.3M | — | Filing → |
| BMEA | BUY | 2022-08-19 | $426K | — | Filing → |